Literature DB >> 9448124

Chief resident experience with laparoscopic cholecystectomy.

G S Ferzli1, M A Fiorillo, N E Hayek, F Sabido.   

Abstract

Resident competence in both open and laparoscopic cholecystectomy (LC) has been a concern among general surgeons. Laparoscopic surgery was late in coming at many surgical residency programs in the United States, and many residents have graduated with limited experience in LC. We are chief residents who were fortunate enough to start our training when LC was first introduced at our institution in 1990. This report summarizes our experience with LC in our chief year, during which we performed LC on 147 patients. The average operating time was 37 minutes (range, 12-82 minutes). Six patients (4%) required conversion to an open procedure. There were three complications (2 postoperative cystic duct leaks and 1 intraoperative common bile duct injury) for an overall complication rate of 2%. There was no mortality. It is our conclusion that graduating chief residents with 5 years' exposure to LC may perform the procedure with a complication rate comparable to that reported in the current literature. Insuring that graduating chief residents have adequate training in open cholecystectomy may become a more pressing issue in the near future.

Entities:  

Mesh:

Year:  1997        PMID: 9448124     DOI: 10.1089/lap.1997.7.147

Source DB:  PubMed          Journal:  J Laparoendosc Adv Surg Tech A        ISSN: 1092-6429            Impact factor:   1.878


  2 in total

1.  Bile duct injury during laparoscopic cholecystectomy: results of a national survey.

Authors:  S B Archer; D W Brown; C D Smith; G D Branum; J G Hunter
Journal:  Ann Surg       Date:  2001-10       Impact factor: 12.969

2.  Is laparoscopy a risk factor for bile duct injury during cholecystectomy?

Authors:  Terrence M Fullum; Stephanie R Downing; Gezzer Ortega; David C Chang; Tolulope A Oyetunji; Kendra Van Kirk; Daniel D Tran; Ian Woods; Edward E Cornwell; Patricia L Turner
Journal:  JSLS       Date:  2013 Jul-Sep       Impact factor: 2.172

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.